130 filings
Page 3 of 7
8-K
bfcdryq6nhaf
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
8-K
xhun3rm
10 Sep 20
Termination of a Material Definitive Agreement
4:02pm
8-K
0aispf kl6sump
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
8-K
xceyiaxaxeitpr
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
8-K
79fphidi95lnmee edyo
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
7alf6p
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
c3zmb5b37r1of
28 May 20
Departure of Directors or Certain Officers
4:16pm
8-K
02w2ey 3ug0s64et8e8
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
jst92qqb
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
di8fbm n5g4gr
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
vk3cz3j1b57fd peb7
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
8-K
a8mrekj
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
8-K
4tcmt
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
qpy1f940
5 Nov 19
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
7:40am
8-K
woowi9uep
10 Sep 19
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
7:39am
8-K
p0wx4hj2ke1ygrc7xd8
7 Aug 19
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
8:08am
8-K
gxsbiqq9rubxfby7
5 Aug 19
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
7:37am
8-K
07azuhea7edjj3rkeh
24 Jul 19
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
6:07am
8-K
vxoxf765yh3nkd4opp
8 Jul 19
Intra-Cellular Therapies Announces PositiveTop-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
7:10am
8-K
z0l36vxlyk0erf
26 Jun 19
Submission of Matters to a Vote of Security Holders
4:31pm